FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

ashington.	D.C.	20549	

on, D.C. 20549	OMB APPROVAL

OMB Number:	3235-0287
Estimated average burden	
hours per response:	0.5

	Check this box if no longer subject to
١	Section 16. Form 4 or Form 5
J	obligations may continue. See
	Instruction 1/h)

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Krieger Nancy					2. Issuer Name and Ticker or Trading Symbol Talaris Therapeutics, Inc. [TALS]										ationship of l c all applicat Director Officer (o			n(s) to Issu 10% Ov Other (s	vner
(Last) (First) (Middle) C/O TALARIS THERAPEUTICS, INC. 93 WORCESTER ST.						3. Date of Earliest Transaction (Month/Day/Year) 02/01/2023									below)	nief Med	dical C	below)	
(Street) WELLESLEY MA 02481 (City) (State) (Zip)					4. If Amendment, Date of Original Filed (Month/Day/Year)							6	i. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person						
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
1. Title of Security (Instr. 3) 2. Trans Date				1		3. Transaction Code (Instr.		ties Acquired (A) or i Of (D) (Instr. 3, 4 and		5. Amount Securities Beneficial Owned Fo		,	Form:	Direct Indirect	7. Nature of Indirect Beneficial Ownership				
							Code	v	Amount	t (A) or Pr		e	Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)		
			Table II -						uired, Di						vned				
1. Title of Derivative Security (Instr. 3)	vative Conversion Date Execution Date, Trans irity or Exercise (Month/Day/Year) if any Code			ansactio	saction Derivative Expiration Date General Decirities (Month/Day/Year)					7. Title an Securities Derivative (Instr. 3 an	Underly Security	ing	8. Price of Derivative Security (Instr. 5)	9. Numb derivativ Securitie Benefici Owned Followin Reporter	e Owner s Form: llly Direct or Indi g (I) (Ins	Ownership	Beneficial Ownership ect (Instr. 4)		
				Co	ode V		(A)	(D)	Date Exercisable		xpiration ate	Title	Amount Number Shares			Transaction(s) (Instr. 4)			
Stock Option (Right to Buy)	\$1.73	02/01/2023			A		120,000		(1)	0	2/01/2033	Common Stock	120,0	000	\$0.00	120,0	000	D	
Stock Appreciation Right	\$1.73	02/01/2023			A		120,000		(2)	0	2/01/2033	Common Stock	120,00	00(2)	\$0.00	0.00 120,000		D	

Explanation of Responses:

- 1. The shares underlying this option shall vest as follows: one-third on August 1, 2023 and the remaining two-thirds on August 1, 2024.
- 1. The shares underlying uns upon shall vest as follows: one-third on August 1, 2023 and the remaining two-thirds on August 1, 2024.

 2. Each Time Vested Stock Appreciation Right ("TV SAR") represents the right to receive either, (i) the largest whole number of shares of stock with a value closest to, but not in excess of, the product of the increase in fair market value of one share of common stock from the date of grant of the TV SAR to the date of exercise of the TV SAR, multiplied by the number of shares of common stock underlying the TV SAR that is being exercised, or (ii) the Company may elect to make cash payment measured by the increase in the fair market value of one share of common stock from the date of grant of the TV SAR to the date of exercise of the TVSAR. One-third of the TV SAR awards will vest on August 1, 2023 and the remaining two-thirds will vest on August 1, 2024. The TV SAR awards expire on February 1, 2033 and have an exercise price of \$1.73 per share, the closing price of the common stock on the grant date.

Remarks:

/s/ Mary Kay Fenton, attorneyin-fact

02/03/2023

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.